

# Stimulating innovation for pandemic preparedness

Ruxandra Draghia-Akli, M.D., Ph.D.  
Global Head, Global Public Health R&D

Broad-spectrum anti-viral therapeutics: A key tool for pandemic preparedness  
Brussels, November 2022

*Johnson & Johnson*

# We mobilized against COVID-19 and continue to advance preparedness programs, from the lab to last mile, with collaborators globally



## Deepening strong scientific collaborations

Expanded our existing partnership with the Biomedical Advanced Research and Development Authority to seek treatment solutions for COVID-19.



## Collaborating across sectors and regions

Founded and co-lead the CARE (Corona Accelerated R&D in Europe) consortium, Europe's largest, multi-partner scientific research initiative dedicated to discovering and developing options for COVID-19 therapeutics, supported by the Innovative Medicines Initiative.



## Exploring the potential of established medicines

Engaged in ACTIV-1, the U.S. National Institutes of Health's late-stage trial to evaluate if immune-modulating therapies can help reduce the need for ventilators for COVID-19 patients and shorten their hospital stay.



## Fostering a network of innovation

Launched the **BLUE KNIGHT initiative** with the Biomedical Advanced Research and Development Authority to **stimulate the innovation and incubation of science and technologies focused on public health threats and emerging infectious diseases.**

# Coming Together to Build the Shield

**BLUE KNIGHT™** is a joint initiative between Johnson & Johnson Innovation – JLABS ('JLABS') and the Biomedical Advanced Research and Development Authority ('BARDA'), part of Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services.

Johnson & Johnson INNOVATION  
— JLABS —



**ASPR**  
ADMINISTRATION FOR STRATEGIC  
PREPAREDNESS AND RESPONSE

 **BLUE KNIGHT™**

Joining forces with the aim to secure a better prepared, protected, and healthier future.

 **BLUE KNIGHT™**

# The Trajectory of BLUE KNIGHT™

Since launching in August 2020, Blue Knight has leveraged the power of public-private partnerships to accelerate innovation and foster partnerships and strategic collaborations to help unlock the collective power of the global community.

The Blue Knight companies have grown from

**7** Companies at launch in Aug. 2020 → **26** Companies in 2022\*



Blue Knight companies are\*:

**36%**  
female-led

**36%**  
minority-led

**68%**  
first-time entrepreneurs

Collectively, Blue Knight companies have raised\*

**\$160M**  
(secured & contingent)

## Blue Knight Companies in the News:

BARDA and JLABS Pick 7 Startups to Battle COVID-19 and Future Pandemics



J&J program adds Ena's infectious disease nasal spray to roster



World Changing Ideas Awards 2021: Health Finalists and Honorable Mentions



Building Better Virus Countermeasures — J&J's BLUE KNIGHT™ Symposium Shows What's Coming



The Sleeping Giants of Vaccine Production Awaken



Glyphic Biotechnologies raises \$6M to accelerate protein sequencing by orders of magnitude



These 3 startups are trying to improve diversity in clinical trials, a challenge experts say will take more than just tech



7 Hills Pharma Receives \$3MM SBIR Grant from NIAID to Accelerate Novel Vaccine Combination Against Chagas Disease



Persephone Biosciences Announces First Participant Enrolled in the ARGONAUT Study of Gut Microbiome-Linked Immune Modulation in Cancer Treatment Response



\* Data current as of Oct. 2022

## Portfolio Snapshot: Decoy Therapeutics



Decoy Therapeutics, Inc. is creating the Imp<sup>3</sup>act Antiviral Drug Discovery Platform that translates vulnerabilities of viruses (including SARS-CoV-2) into highly effective drug candidates in hours of sequencing a virus.

### Upcoming Milestones

- Launch preclinical testing of a second drug program
- Initial Series A raise of \$35M



**Rick Pierce**  
Co-Founder & CEO

---

“Decoy’s rapid antiviral drug development platform is poised to change how governments prepare and defend against future pandemic and endemic viral threats.”

# Join us in expanding the BLUE KNIGHT™ ecosystem

<https://jnjinovation.com/jlabs/blue-knight>



**We will continue to set our agenda to take on entrenched and emerging global health threats, from discovery to data sciences, and expanding clinical trials networks.**

**Through collaboration, we can ensure that advancements from the lab reach communities from the first to last mile, especially when they matter most.**



**Deepening strong scientific collaborations**



**Exploring the potential of new therapies**



**Collaborating across sectors and regions**



**Fostering a network of innovation**

*Johnson & Johnson*